Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 6/20 | 0.53 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP4 | P49662 | 1/20 | 0.45 |
| ▸ | CASP5 | P51878 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.45 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613501 | 1.00 | PSENEN (0.55) | PSENENCTSDRENCTSKCTSB | |
| SCHEMBL5176929 | 0.96 | CTSD (0.53) | PSENENCTSDRENCTSKCTSB | |
| SCHEMBL22989798 | 0.91 | CTSD (0.44) | PSENENCTSDRENCTSKCTSS | |
| SCHEMBL7610443 | 0.91 | CTSS (0.48) | PSENENCTSDRENCTSKCASP1 | |
| SCHEMBL7610438 | 0.91 | CTSS (0.48) | PSENENCTSDRENCTSKCASP1 | |
| SCHEMBL30544517 | 0.90 | PSENEN (0.47) | PSENENCTSDRENCTSKCTSB | |
| SCHEMBL30544518 | 0.90 | PSENEN (0.47) | PSENENCTSDRENCTSKCTSB | |
| SCHEMBL9754306 | 0.84 | PSENEN (0.71) | PSENENCTSDRENCTSKCTSS | |
| SCHEMBL10144106 | 0.81 | PSENEN (0.45) | PSENENCTSDRENCTSKCTSS | |
| SCHEMBL21737914 | 0.81 | REN (0.47) | PSENENRENCTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | N-ZYME BIOTECH GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | TGM2, GNMT, TGM1 | PSENEN 1959/4885CTSD 2966/4885REN 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.